智通财经APP讯,华东医药(000963.SZ)发布公告,2024年11月27日,公司全资子公司杭州中美华东制药有限公司(“中美华东”)收到国家药品监督管理局(NMPA)核准签发的《药品注册证书》,中美华东申报的索米妥昔单抗注射液(爱拉赫®/ELAHERE®)用于既往接受过1-3线系统性治疗的叶酸受体α阳性的铂类耐药卵巢癌(PROC)适应症的上市许可申请获得批准。据悉,索米妥昔单抗注射液为中美华东...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.